53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.
8 citations
,
June 2017 in “Steroids” This study evaluated novel steroid compounds for their ability to inhibit 5α-reductase, showing that compound 16a significantly reduced rat prostate weight more than epristeride and exhibited excellent in vitro inhibitory potency, indicating its potential as a lead candidate for further benign prostatic hyperplasia drug research.
11 citations
,
May 1996 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study reported that 5 alpha-reductase type 2 is the predominant enzyme in pubic skin fibroblasts across normal men, women, and hirsute patients, suggesting potential treatment options for idiopathic hirsutism.
January 2014 in “프로그램북(구 초록집)” This article reviews updates on 5 alpha-reductase inhibitors for treating male pattern hair loss and presents no new clinical findings; the author aims to enhance understanding of these therapies.
February 2017 in “대한피부과학회지” This case report describes a 52-year-old man with androgenic alopecia who experienced improvement after adding low-dose dutasteride to long-term finasteride treatment when the initial therapy's effectiveness waned.